Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997016221) GENETIC INDUCTION OF RECEPTORS FOR TARGETED RADIOTHERAPY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016221 International Application No.: PCT/IB1996/001277
Publication Date: 09.05.1997 International Filing Date: 30.10.1996
Chapter 2 Demand Filed: 29.05.1997
IPC:
A61K 38/00 (2006.01) ,A61K 38/17 (2006.01) ,A61K 48/00 (2006.01) ,A61K 51/08 (2006.01) ,A61K 51/10 (2006.01) ,C07K 14/705 (2006.01) ,C07K 14/82 (2006.01) ,C07K 16/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
02
characterised by the carrier
04
Organic compounds
08
Peptides, e.g. proteins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
02
characterised by the carrier
04
Organic compounds
08
Peptides, e.g. proteins
10
Antibodies or immunoglobulins; Fragments thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
82
Translation products from oncogenes
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
THE UAB RESEARCH FOUNDATION [US/US]; The University of Alabama at Birmingham 1120-G Administration Building 701 20th Street South Birmingham, AL 35924-0111, US
Inventors:
BUCHSBAUM, Donald, J.; US
RABEN, David; US
KHAZAELI, Mohammad, B.; US
STACKHOUSE, Murray; US
CURIEL, David; US
Agent:
ADLER, Benjamin, Aaron; McGregor & Adler, P.C. 8011 Candle Lane Houston, TX 77071, US
Priority Data:
60/008,14731.10.1995US
Title (EN) GENETIC INDUCTION OF RECEPTORS FOR TARGETED RADIOTHERAPY
(FR) INDUCTION GENIQUE DE RECEPTEURS POUR RADIOTHERAPIE CIBLEE
Abstract:
(EN) The present invention provides a method to achieve radioisotopic localization at tumor sites, i.e., a method of enhancing radiolabeled ligand localization to a tumor in an individual in need of such treatment, comprising the steps of: transducing said tumor with a gene encoding a membrane expressed protein unique to said tumor; and administering to said individual a radiolabeled ligand which specifically binds to said protein. The use of gene therapy technology to induce expression of high affinity membrane molecules/receptors can enhance the specificity of radioisotope localization while the use of radioactive isotopes with the ability to deliver radiation damage across several cell diameters will compensate for less than perfect transduction efficiency.
(FR) Cette invention porte sur un procédé visant à permettre un repérage radio-isotope de sites tumoraux, c'est à dire un procédé améliorant le repérage d'un ligand radiomarqué sur une tumeur chez un individu ayant besoin de ce traitement. Le procédé consiste à effectuer une transduction de ladite tumeur à l'aide d'un gène codant une protéine membranaire exprimée, propre à cette tumeur, et à administrer audit individu un ligand radiomarqué se liant de manière spécifique à ladite protéine. Le recours à la technique de thérapie génique pour induire l'expression de molécules/récepteurs membranaires à spécificité élevée peut améliorer la spécificité du repérage radio-isotope tandis que l'emploi d'isotopes radioactifs capables de causer un dommage par rayonnement dans plusieurs diamètres de cellules compense une efficacité de la transduction que l'on ne saurait qualifier de parfaite.
Designated States: AU, CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0858506JP2000500438 CA2234102AU1996075032